FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT	OF CHANGES IN	I BENEFICIAL	OWNERSHIP

OMB APPROVAL								
OMB Number:	3235-0287							
Estimated average b	ourden							
hours per response:	0.5							

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>RIEDEL NORBERT G</u>						2. Issuer Name and Ticker or Trading Symbol Eton Pharmaceuticals, Inc. [ETON]									ationship o all applic Directo	,		rson(s) to Issuer 10% Owner		
(Last) 21925 W	`	irst) KWY, SUITE 23	(Middle)		3. Date of Earliest Transaction (Month 05/03/2021						ay/Year)				Officer below)	icer (give title ow)		Other (s below)	pecify	
(Street) DEER PA			60010-727 (Zip)	78	4. 1	f Ame	endment, I	dment, Date of Original Filed (Month/Day/Year)						Indiv ne) X						
	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																			
1. Title of Security (Instr. 3) 2. Transa Date (Month/D					Execution Date,		3. Transac Code (Ir 8)				ed (A) or tr. 3, 4 ar	and Securitie		es Formally (D) (Following (I) (I		: Direct r Indirect str. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)			
								Code	V	Amount	(A) or (D)			Transaction(s) (Instr. 3 and 4)				(111311. 4)		
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																			
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution I if any (Month/Day	Date, T	Code		of E		6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Am of Securities Underlying Derivative Secu (Instr. 3 and 4)		Do	8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficiall Owned Following Reported Transactio (Instr. 4)	ly Ov Fo Dii or (I)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
					Code	v	(A)		Date Exercisable		xpiration ate	Title	Amoun or Numbe of Shares							
Stock Option (Right to buy)	\$8.61	05/03/2021			A		19,655		(1)	0	5/03/2031	Common Stock	19,65	5	\$0.00	59,555	5	D		

Explanation of Responses:

1. The shares subject to the option shall vest on a quarterly basis over 12 months from the date of grant until fully vested and exercisable on May 3, 2022.

/s/ W. Wilson Troutman

05/05/2021

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.